Clinical Trial Update: Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen

View source ↗

Summary

This completed clinical trial evaluated tolerability and quality of life in people who switched to the Avonex Pen (interferon beta-1a) for relapsing forms of mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinical Isolated Syndrome
• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Avonex PEN (interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis, Clinical Isolated Syndrome (CIS) | Status: COMPLETED